z-logo
open-access-imgOpen Access
Nonfamilial,MPLS505N-Mutated Essential Thrombocythaemia
Author(s) -
Ruth Morrell,
Stephen E. Langabeer,
Liam Smyth,
M.K.D.I. Perera,
Gerard Crotty
Publication year - 2013
Publication title -
case reports in hematology
Language(s) - English
Resource type - Journals
eISSN - 2090-6560
pISSN - 2090-6579
DOI - 10.1155/2013/729327
Subject(s) - medicine , myelofibrosis , exon , bone marrow , mutation , thrombopoietin receptor , pedigree chart , thrombopoietin , pathology , cancer research , genetics , gene , biology , haematopoiesis , stem cell
Mutations of MPL are present in a significant proportion of patients with the myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF), and essential thrombocythaemia (ET). The most frequent of these mutations, W515L and W515K, occur in exon 10 of MPL , which encodes the receptor for thrombopoietin. Another exon 10 mutation, MPL S505N, has been shown to be a founder mutation in several pedigrees with familial thrombocythaemia where it is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Rare cases of sporadic, nonfamilial, MPL S505N MPN have been documented, but the presenting laboratory and clinical features have not been described in detail. The diagnosis and clinical course of a case of MPL S505N-positive MPN are presented with diagnostic features and treatment response resembling typical ET but with evidence of increasing bone marrow fibrosis. Further MPN cases possessing this genotype require reporting in order to ascertain whether any particular morphological or clinical features, if present, determine clinical course and aid the refinement of therapeutic options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom